Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

NCT02659384 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

122

Enrollment

NETWORK

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: Bevacizumab
DRUG: atezolizumab
DRUG: acetylsalicylic acid
DRUG: placebo

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC